Prognosis and Decision-making Analysis of Contralateral Prophylactic Mastectomy among female patients with stage 0–III unilateral breast cancer in Chinese population: a retrospective cohort study
Author:
zhu jingjin1, min ningning1, zhang yanjun2, wu huan2, hong chenyan1, geng rui2, wei yufan1, guan qingyu1, zheng yiqiong2, li xiru2ORCID
Affiliation:
1. Nankai University 2. Chinese PLA General Hospital
Abstract
Abstract
Purpose
It was demonstrated that contralateral prophylactic mastectomy (CPM) provides no survival benefit for patients with average risk breast cancer, but the application in patients with early-stage breast cancer has increased. This study aims to explore the application trend, survival benefits, decision-making factors, and satisfaction of CPM based on the patients undergoing CPM in a Chinese institution.
Methods
The 0-III stage unilateral breast cancer (UBC) patients who received breast surgery in the First Medical Center of the PLA General Hospital from 2005 to 2017 were selected. The surgical procedures include simple mastectomy (SM), nipple-sparing mastectomy (NSM) and breast conserving surgery (BCS). Those patients who underwent preventive breast surgery on the healthy side were defined as the CPM group. The Cochran Armitage trend test was used to compare the longitudinal application trend of the annual surgical number and proportion of the four surgical procedures. Cox proportional regression analysis and Kaplan-Meier curve were performed to compare the overall survival (OS) and disease free survival (DFS) rates between CPM group and unilateral mastectomy (UM) group. Proportional propensity score matching (PSM) with a 1:1 ratio was used to match the two groups and secondary survival analysis was performed. Logistic regression models were used to test predictive factors related to patients' CPM surgical decision-making. A self-made satisfaction rating scale were used to analyze the satisfaction of CPM procedure and the impact on quality of life.
Results
4,276 patients were included in the study, with 73 (1.7%) patients receiving CPM, 3567 (83.4%) receiving SM, 151 (35.3%) receiving NSM, and 485 (11.3%) receiving BCS. CPM surgery was first used in 2007, with a peak application rate of 3.02% in 2016 and a decrease to 1.05% in 2017. 3,791 patients with CPM and UM were included in the survival analysis, with a median follow-up time of 66.60 months. Compared to UM patients, neither the KM survival curve nor Cox regression hazard analysis of CPM showed better OS (p = 0.963; p = 0.834). After PSM, CPM also did not exhibit significant survival benefits in OS (HR 0.876, 95% CI 0.253–3.034, p = 0.335) and DFS (HR 0.922, 95% CI 0.629–1.352, p = 0.409). The logistic regression analysis showed that NSM surgery and early TNM stage were independent factors to promote the CPM decision-making of patients. 73 patients in the CPM group showed high overall satisfaction (84.9%) and relatively low physical satisfaction (69.9%). And a significant percentage of patients expressed that the physical labor was affected.
Conclusion
Our study suggested CPM does not provide any OS and DFS survival benefits compared to UM. Although most patients with CPM were generally satisfied, many gave a low evaluation of cosmetic results. Therefore, clinicians should fully communicate with patients before surgery and be more cautious in giving CPM recommendations.
Publisher
Research Square Platform LLC
Reference41 articles.
1. 1. Storm, H.H.; Jensen, O.M. Risk of contralateral breast cancer in Denmark 1943-80. Br J Cancer 1986, 54, 483–492, doi:10.1038/bjc.1986.201. 2. 2. Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; Phillips, K.A.; Mooij, T.M.; Roos-Blom, M.J.; Jervis, S.; van Leeuwen, F.E.; Milne, R.L.; Andrieu, N.; et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama 2017, 317, 2402–2416, doi:10.1001/jama.2017.7112. 3. 3. Rhiem, K.; Engel, C.; Graeser, M.; Zachariae, S.; Kast, K.; Kiechle, M.; Ditsch, N.; Janni, W.; Mundhenke, C.; Golatta, M.; et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012, 14, R156, doi:10.1186/bcr3369. 4. 4. Forbes, J.F.; Cuzick, J.; Buzdar, A.; Howell, A.; Tobias, J.S.; Baum, M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9, 45–53, doi:10.1016/s1470-2045(07)70385-6. 5. 5. Kurian, A.W.; Lichtensztajn, D.Y.; Keegan, T.H.; Nelson, D.O.; Clarke, C.A.; Gomez, S.L. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. Jama 2014, 312, 902–914, doi:10.1001/jama.2014.10707.
|
|